Eli Lilly participated in a $57.6m round that will support the identification and preclinical development of Cedilla's first two small molecule product candidates.
US-based small molecule drug developer Cedilla Therapeutics completed a $57.6m series B round yesterday that included pharmaceutical firm Eli Lilly.
Casdin Capital and Boxer Capital co-led the round, which also featured asset manager Schroder Adveq, venture capital firm Third Rock Ventures and unnamed institutional investors.
Cedilla is working on small molecule therapeutics to treat diseases caused by protein dysregulation, including cancer. The capital will fund the progression of its product pipeline, including identifying its first two drug candidates and beginning…
